We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 1,825

Bristol Myers’ Celgene gamble, Apple’s IPR attack on Qualcomm, 2018’s US patent litigation stats, key CRISPR facts, plus much more
  • IAM
  • Global
  • January 20 2019

Patent office officials in Beijing reveal the country's top patent recipients, amount of cross-border royalty flows and ambiguous data on foreign


The Final Score: 2018 Drug & Biologic Patent Approvals
  • Dilworth IP
  • USA
  • January 15 2019

The past year was a big year for FDA approved new drugs and biologics - 59 in fact, compared to 46 in 2017 and a mere 22 in 2016. From the published


Amerigen Pharmaceuticals v. UCB Pharma Gmbh
  • Knobbe Martens
  • USA
  • January 14 2019

A generic pharmaceutical company had standing to appeal the Board’s decision in an IPR that claims of a patent were not obvious even though it may be


The 2019 U.S. Federal Government Shutdown and its Potential Impact on Biologics
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • January 9 2019

On December 22, 2018, the United States federal government entered a partial shutdown, which now enters its 19th day. If the shutdown continues


Linking It Up: Antibody-Drug Conjugates
  • Dilworth IP
  • USA
  • January 8 2019

As discussed in our previous article, antibody-drug conjugates (ADCs) have emerged as a highly promising class of anti-cancer drugs, and significant


2018 Highlights in Canadian Life Sciences IP
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 7 2019

In 2018 we reported on a number of developments in life sciences IP and regulatory law. Our most-read articles were: 1 a June update on biosimilars


Written Description in Amgen v. Sanofi: Is the Federal Circuit Possessed? Will SCOTUS Grant Certiorari?
  • Mintz
  • USA
  • January 2 2019

In the continuing Amgen v. Sanofi saga, Amgen has asked SCOTUS to take up the issue of written description, which is currently established by showing


A Sufficient Controversy Exists When a Second ANDA Filer Seeks DJ of Noninfringement of an Orange-Book-Listed Patent Owned but Disclaimed by Brand Name Manufacturer
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • December 30 2018

In Apotex Inc. v. Daiichi Sankyo, Inc., Nos. 14-1282, -1291 (Fed. Cir. Mar. 31, 2015), the Federal Circuit reversed the district court’s dismissal of


Inherency and Obviousness
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • December 27 2018

This case provides an example of the use of inherency in an obviousness determination. That is, the Northern District Court of Illinois found that


Risky Business: Due Diligence for Early-Stage Life Sciences Companies
  • McDermott Will & Emery
  • USA
  • December 26 2018

The life sciences industry has changed dramatically over the last 10 years: cancer treatments using a patient’s own immune system to selectively kill